Aptadir Therapeutics
Milan, Italy
◆ Total Raised
$90.6M
◆ Stage
seed
◆ Location
Milan, Italy
◆ Founded
2024
◆ Team size
1-10
◆ About Aptadir Therapeutics
Milan-based biotech developing RNA therapies to reactivate the FMR1 gene silenced in Fragile X syndrome.
◆ What sets it apart
It uses RNA-based gene-reactivation chemistry to unsilence disease-causing genes, aiming for disease-modifying effects rather than symptom management.
◆ Sectors
◆ Business
Modeltransactional
CustomerBiopharma partners, clinicians, and ultimately patients with Fragile X syndrome and other genetically defined diseases
◆ Notable
- Raised a €40M seed round led by 4BIO Capital on 2026-09-29
- Previously raised about $1.6M in pre-seed funding from EXTEND
- Identified CAP1-FMR1 as a lead candidate for Fragile X syndrome
◆ Backing funds on Raise
- Angelini Venturesseed
- Large Venturesseed
◆ Funding rounds
29 Sept 2026
Led by 4BIO Capital
With EXTEND, CDP Venture Capital, Indaco Venture Partners, XGEN Venture, CE-Ventures, Angelini Ventures, Kerna Ventures, Italian Angels for Biotech, Club degli Investitori
◆ Explore the market
◆ FAQ
What does Aptadir Therapeutics do?
Milan-based biotech developing RNA therapies to reactivate the FMR1 gene silenced in Fragile X syndrome.
Where is Aptadir Therapeutics based?
Aptadir Therapeutics is based in Milan, Italy, founded in 2024.
How much has Aptadir Therapeutics raised?
Aptadir Therapeutics has raised $90.6M in tracked funding and is currently at the seed stage.
Who has invested in Aptadir Therapeutics?
Investors in Aptadir Therapeutics include 4BIO Capital, EXTEND Initiative, CDP Venture Capital, Angelini Ventures, Evotec SE and Crescent Enterprises.